Display options
Share it on

Plast Reconstr Surg Glob Open. 2015 Sep 22;3(9):e520. doi: 10.1097/GOX.0000000000000503. eCollection 2015 Sep.

Tissue Inhibitor of Metalloproteinase-2 Suppresses Collagen Synthesis in Cultured Keloid Fibroblasts.

Plastic and reconstructive surgery. Global open

Teruyuki Dohi, Koichi Miyake, Masayo Aoki, Rei Ogawa, Satoshi Akaishi, Takashi Shimada, Takashi Okada, Hiko Hyakusoku

Affiliations

  1. Department of Plastic, Reconstructive and Aesthetic Surgery, Nippon Medical School, Tokyo, Japan; and Department of Biochemistry and Molecular Biology, Division of Gene Therapy, Center for Advanced Medical Technology, Nippon Medical School, Tokyo, Japan.

PMID: 26495233 PMCID: PMC4596445 DOI: 10.1097/GOX.0000000000000503

Abstract

BACKGROUND: Keloids are defined as a kind of dermal fibroproliferative disorder resulting from the accumulation of collagen. In the remodeling of extracellular matrix, the balance between matrix metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases (TIMPs) is as critical as the proper production of extracellular matrix. We investigate the role of TIMPs and MMPs in the pathogenesis of keloids and examine the therapeutic potential of TIMP-2.

METHODS: The expression of TIMPs and MMPs in most inflamed parts of cultured keloid fibroblasts (KFs) and peripheral normal skin fibroblasts (PNFs) in the same individuals and the reactivity of KFs to cyclic mechanical stretch were analyzed by quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay (n = 7). To evaluate the effect of treating KFs with TIMP-2, collagen synthesis was investigated by quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay, and microscopic analysis was used to examine the treatment effects of TIMP-2 on ex vivo cultures of keloid tissue (n = 6).

RESULTS: TIMP-2 was downregulated in cultured KFs compared with PNFs in the same individuals, and the reduction in TIMP-2 was exacerbated by cyclic mechanical stretch. Administration of TIMP-2 (200 or 300 ng/mL) significantly suppressed expression of Col1A2 and Col3A1 mRNA and collagen type I protein in KFs. TIMP-2 also significantly reduced the skin dermal and collagen bundle thickness in ex vivo cultures of keloid tissue.

CONCLUSION: These results indicated that downregulation of TIMP-2 in KFs is a crucial event in the pathogenesis of keloids, and the TIMP-2 would be a promising candidate for the treatment of keloids.

References

  1. Am J Cancer Res. 2011;1(4):482-97 - PubMed
  2. J Biol Chem. 2001 Oct 19;276(42):38502-10 - PubMed
  3. Wound Repair Regen. 2010 Mar-Apr;18(2):139-53 - PubMed
  4. Am J Dermatopathol. 2013 Feb;35(1):64-73 - PubMed
  5. Sci Transl Med. 2012 May 30;4(136):136ra71 - PubMed
  6. Am J Pathol. 2011 Nov;179(5):2589-600 - PubMed
  7. Sci Signal. 2008 Jul 08;1(27):re6 - PubMed
  8. Ann Plast Surg. 2008 Apr;60(4):445-51 - PubMed
  9. Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33 - PubMed
  10. J Plast Reconstr Aesthet Surg. 2013 Dec;66(12):e351-61 - PubMed
  11. Plast Reconstr Surg. 2004 Jul;114(1):229-36 - PubMed
  12. Ann Rheum Dis. 2001 Sep;60(9):846-51 - PubMed
  13. Lab Invest. 2004 Jan;84(1):8-20 - PubMed
  14. Exp Cell Res. 1993 May;206(1):63-71 - PubMed
  15. Int J Surg. 2007 Aug;5(4):278-85 - PubMed
  16. J Biol Chem. 2003 Mar 21;278(12):10304-13 - PubMed
  17. Clin Chim Acta. 1999 Mar;281(1-2):109-20 - PubMed
  18. Nature. 2008 May 15;453(7193):314-21 - PubMed
  19. Br J Dermatol. 2011 Jan;164(1):83-96 - PubMed
  20. Circ Res. 2010 Mar 5;106(4):796-808 - PubMed
  21. Wound Repair Regen. 1999 Nov-Dec;7(6):477-85 - PubMed
  22. J Invest Dermatol. 1990 Feb;94(2):187-90 - PubMed
  23. J Lab Clin Med. 2002 Apr;139(4):202-10 - PubMed
  24. Dis Model Mech. 2010 May-Jun;3(5-6):317-32 - PubMed
  25. Br J Oral Maxillofac Surg. 2006 Dec;44(6):482-6 - PubMed
  26. J Am Acad Dermatol. 2010 Sep;63(3):483-9 - PubMed
  27. Intervirology. 2001;44(4):227-31 - PubMed
  28. Cardiovasc Res. 2006 Feb 15;69(3):562-73 - PubMed
  29. J Biol Chem. 1990 Aug 15;265(23):13933-8 - PubMed
  30. FASEB J. 2004 May;18(7):816-27 - PubMed
  31. Histopathology. 2009 May;54(6):722-30 - PubMed
  32. Blood. 2008 Aug 15;112(4):1120-8 - PubMed
  33. Semin Liver Dis. 2010 Aug;30(3):245-57 - PubMed
  34. J Invest Dermatol. 2014 Mar;134(3):818-26 - PubMed
  35. J Biol Chem. 1998 Sep 18;273(38):24360-7 - PubMed
  36. Lung. 2011 Aug;189(4):341-9 - PubMed
  37. Exp Dermatol. 2003;12 Suppl 2:35-42 - PubMed
  38. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):183-9 - PubMed
  39. Exp Mol Med. 2010 Jan 31;42(1):38-46 - PubMed
  40. J Biol Chem. 1989 Oct 15;264(29):17374-8 - PubMed
  41. Am J Pathol. 1997 May;150(5):1647-59 - PubMed
  42. Trends Mol Med. 2005 Mar;11(3):97-103 - PubMed
  43. Wound Repair Regen. 2012 Mar-Apr;20(2):149-57 - PubMed
  44. J Invest Dermatol. 2014 Jul;134(7):2041-3 - PubMed
  45. Cancer Biol Ther. 2006 Dec;5(12):1640-6 - PubMed
  46. Biomed Res Int. 2013;2013:621538 - PubMed
  47. Open Rheumatol J. 2008;2:17-22 - PubMed
  48. J Dent Res. 2000 Sep;79(9):1712-6 - PubMed
  49. J Plast Reconstr Aesthet Surg. 2010 Jun;63(6):1015-21 - PubMed

Publication Types